Experience with multiple endocrine neoplasia type 1 screening.
Screening for multiple endocrine neoplasia type 1 (MEN1) may be conducted for a variety of reasons. The principal aims may be more or less scientific, such as early identification of the trait. Other reasons for screening comprise attempts to avoid endocrine morbidity and possibly forthcoming problems from malignant transformation, as well as attempts to identify and treat gene carriers with a clinically overt disease. Several reports have substantiated the diagnostic yield from screening efforts among MEN1 kindreds. Such increases in detection of the disease ideally should be accompanied by enhanced rates of survival in order to fully justify an unlimited search for the trait. However, studies are lacking a clearly verifying reduction of mortality from the detection of presymptomatic MEN1 individuals. While waiting for the results of survival studies in progress, the generally prevailing opinion favours widespread screening because of the evidently decreased morbidity resulting from early diagnosis of the MEN1 trait, which apparently persists even during decades of follow-up. This paper presents the clinical features of the disease and experience derived from a prospective screening programme for MEN1 detection.
Skogseid
B
B
Department of Internal Medicine University Hospital, Uppsala, Sweden.
Oberg
K
K
D002471:Cell Transformation, Neoplastic; D003663:Decision Trees; D004700:Endocrine System Diseases / Q000235:genetics / Q000517:prevention & control*; D006579:Heterozygote; D006801:Humans; D008403:Mass Screening; D018761:Multiple Endocrine Neoplasia Type 1 / Q000150:complications / Q000175:diagnosis*; D011446:Prospective Studies; D016019:Survival Analysis